Medical Device Policy is a progressive step in propelling the country towards Atmanirbharta in the heavily import dependent Medical Device Sector
Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239
US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore
Dr. Mandaviya urged the stakeholders to capitalize on the current opportunities
Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.
The product is expected to be launched in June 2023
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
Indian government seeks to promote collaboration with stakeholders and harness potential for achieving growth and development of sector
Product deliveries scheduled in Q3 of 2023
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
Subscribe To Our Newsletter & Stay Updated
